MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Inicio・Lista de Acciones・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Cerrado

SectorSanidad

339.06 1.82

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

329.96

Máximo

343.01

Métricas clave
By Trading Economics
Ingresos	-65M 186M
Ventas	-152M 1.1B
P/B Media del Sector	141.777 66.418
BPA	1.25
Margen de beneficios	16.993
Empleados	2,500
EBITDA	-152M 145M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+35.88% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.5B 44B
Apertura anterior	337.24
Cierre anterior	339.06

Noticias sobre sentimiento de mercado

By Acuity

50%

154 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

256.565 / 269.81 Soporte y Resistencia

Alnylam Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 abr 2026, 23:25 UTC

Noticias de Eventos Importantes

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 abr 2026, 22:45 UTC

Noticias de Eventos Importantes

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 abr 2026, 18:03 UTC

Ganancias

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 abr 2026, 23:58 UTC

Ganancias

Review & Preview: Earnings Time -- Barrons.com

13 abr 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 abr 2026, 23:20 UTC

Charlas de Mercado

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 abr 2026, 23:01 UTC

Ganancias

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 abr 2026, 23:01 UTC

Ganancias

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 abr 2026, 23:01 UTC

Ganancias

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 abr 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 abr 2026, 21:53 UTC

Ganancias

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 abr 2026, 21:26 UTC

Noticias de Eventos Importantes

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 abr 2026, 21:23 UTC

Ganancias

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 abr 2026, 21:16 UTC

Ganancias

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

13 abr 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 abr 2026, 20:34 UTC

Ganancias

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 abr 2026, 19:59 UTC

Charlas de Mercado

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 abr 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 abr 2026, 19:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Correction to Precious Metals Market Talk on April 9

13 abr 2026, 19:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 abr 2026, 18:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 abr 2026, 18:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 abr 2026, 18:43 UTC

Charlas de Mercado

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Comparación entre iguales

Cambio de precio

Alnylam Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

35.88% repunte

Estimación a 12 Meses

Media 452.47 USD 35.88%

Máximo 549 USD

Mínimo 330 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alnylam Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

Comprar

Mantener

Vender

De acuerdo con 20 analistas que ofrecen calificaciones bursátiles a para Alnylam Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

256.565 / 269.81Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

154 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.